Effect of PRM-125 on Ambulatory Blood Pressure

• Status: Recruiting
• Trial end date: 2022-11-30
• Target enrollment: 0
• Participant gender: All

Summary

Evaluation of Once-Daily PRM125 On Ambulatory Blood Pressure in Adults with Hypertension

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: PRM Pharma, LLC

Criteria

Inclusion Criteria:

• primary hypertension

Exclusion Criteria:

• medical conditions that preclude evaluation and/or adversely effect subject safety